Zydus Cadila trades flat despite getting nod for Fluphenazine Hydrochloride tablets

Fluphenazine Hydrochloride tablets are used in the treatment of a certain type of mental or mood-related condition (schizophrenia).

Zydus Cadila announced of receiving final approval from USFDA for marketing market Fluphenazine Hydrochloride tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg.  

Fluphenazine Hydrochloride tablets are used in the treatment of a certain type of mental or mood-related condition (schizophrenia). Fluphenazine is said to belong to a class of medications, which are commonly known as phenothiazines or sometimes, also referred to as a neuroleptic.  

As per the press release, Fluphenazine Hydrochloride tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg, will be manufactured at Zydus Cadila’s formulation manufacturing facility located at SEZ in Ahmedabad.   

Recently, the company also announced introducing a new feature in the packaging of its critical drugs that will further help patients to identify if the purchased product is not fake or counterfeited. It has incorporated a new IT-enabled scratch code that is printed under a scratchable surface through which, patients can identify its genuinity by scratching the surface and verifying the code via the app or website.  

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures & markets a broad range of healthcare therapies.  

On Monday, the stock of the company was seen trading at Rs 617.50 per share, down by 0.60 per cent or Rs 3.75 per share. The 52-week high is Rs 673.70 per share and the 52-week low is Rs 341.50 per share on BSE.